Late‑phase delays often trace back to early research decisions. Unmatched Beginnings for Late‑Phase Success shows how early manufacturing and CMC choices—in plasmids, materials, and partners—can reduce risk, streamline development, and support faster regulatory review in cell and gene therapy programs.